Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma

PURPOSE: In the Phase III SIROCCO trial (NCT01928771), benralizumab significantly reduced asthma exacerbations and improved lung function and symptoms for patients with severe, uncontrolled eosinophilic asthma. The aim of this subgroup analysis was to evaluate efficacy and safety of benralizumab for...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Allergy Asthma Immunol Res
Huvudupphovsmän: Park, Hae-Sim, Lee, Sang Haak, Lee, Sook Young, Kim, Mi-Kyeong, Lee, Byung Jae, Werkström, Viktoria, Barker, Peter, Zangrilli, James G.
Materialtyp: Artigo
Språk:Inglês
Publicerad: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2019
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6557768/
https://ncbi.nlm.nih.gov/pubmed/31172719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4168/aair.2019.11.4.508
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk